GT 201
Alternative Names: GT-201Latest Information Update: 10 Jul 2024
At a glance
- Originator GRIT Biotechnology
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
- Clinical Phase Unknown Gynaecological cancer; Lung cancer; Non-small cell lung cancer
Most Recent Events
- 31 May 2024 Adverse events and efficacy data from phase-I/II trials in Solid tumours presented at 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 02 Feb 2024 Clinical trials in Non-small cell lung cancer (Combination therapy) in China (unspecified route) (NCT06235242)
- 31 Jan 2024 Grit Biotechnology plans a clinical trial for Non small cell lung cancer (Combination therapy) in China (Injection), in January 2024 (NCT06235242)